• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

    7/21/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email

    SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

    Individuals can access the conference call by dialing:

    US domestic callers: (888) 346-3970

    Outside US callers: (412) 902-4297

    Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.

    About Standard BioTools Inc.

    Standard BioTools Inc. (NASDAQ:LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

    Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

    Patent and License Information: standardbio.com/legal/notices.

    ©2025 Standard BioTools Inc. All rights reserved.

    Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

    Investor Contact:

    Marissa Bych

    [email protected]



    Primary Logo

    Get the next $LAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    8/13/2025$1.55Buy → Hold
    TD Cowen
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/15/25 9:18:22 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Kim Hanjoon Alex was granted 1,500,000 shares, increasing direct ownership by 159% to 2,440,564 units (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/5/25 6:33:03 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Egholm Michael was granted 3,000,000 shares, increasing direct ownership by 110% to 5,736,285 units (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/5/25 6:23:22 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    SEC Filings

    View All

    SEC Form S-8 filed by Standard BioTools Inc.

    S-8 - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    8/15/25 4:11:45 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Standard BioTools Inc.

    10-Q - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    8/15/25 4:05:59 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form NT 10-Q filed by Standard BioTools Inc.

    NT 10-Q - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    8/11/25 8:19:25 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Standard BioTools Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

    8/11/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

    PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan's strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to run 100,000 plasma samples from the PRECISE-SG100K biobank following a comprehensive evaluation of competitive proteomics offerings. The combination of unmatched proteome coverage, superior reproducibility and high-quality service offering

    8/6/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

    SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

    7/21/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Standard BioTools downgraded by TD Cowen with a new price target

    TD Cowen downgraded Standard BioTools from Buy to Hold and set a new price target of $1.55

    8/13/25 8:03:50 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

    2/27/25 6:22:46 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    TD Cowen initiated coverage on Standard BioTools with a new price target

    TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

    4/16/24 8:09:43 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/15/25 9:18:22 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    3/4/25 8:19:51 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/29/24 8:30:41 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    View All

    Standard BioTools Appoints Alex Kim as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

    11/7/24 8:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

    5/15/23 7:30:14 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Financials

    Live finance-specific insights

    View All

    Standard BioTools Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

    8/11/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

    SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

    7/21/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Reports First Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

    5/6/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/14/24 3:32:10 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/12/24 6:01:47 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/4/24 1:59:57 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials